EGAGenomicsIllumina HiSeq 2000Cancer Genomicshttps://ega-archive.org/studies/EGAS00001000280EGAEGA study EGAS00001000280Chordoma Targeted Sequencing StudyEGArestrictedCHDM, study., Chordomas, susceptibility to chordoma, chordoma, susceptibility tophapii, screening, IPP2A2, findings, Complete Exome Sequencings, Procedures, Complete Exome, Exome, igaad, StF-IT-1, Procedure, chordoma, PHAPII, group, 5730420M11Rik, method, Techniques, Exome Sequencing, Client., I-2PP2A, Method, method used in an experiment, Dm I-2, I2PP2A, Studies, symptoms, CHDM, Whole Transcriptome, Transcriptome Sequencing, Chordomas, Library, Technique, study, SET, WES, Complete Transcriptome, Complete, Complete Transcriptome Sequencing, Exome Sequencings, HLA-DR-associated protein II, ensemble, DI-2, susceptibility to chordoma, TAF-I, Complete Exome Sequencing, I-2Dm, susceptibility to, Whole Transcriptome Sequencing, ipp2a2, signs, 2pp2a, patient, Methodological, whole genome, CG4299, Methodological Study, Sequencing, CG10574, plan specification, DmelCG4299, I-2PP1, Study, IGAAD, set, dSET/TAF-Ibeta, Whole Exome, 2610030F17Rik, TAF-IBETA, 2PP2A, Methodological Studies, DmelCG10574, Patient, taf-ibeta, Clients, Whole, Whole Exome Sequencing, dSET, dSet, TAF-Ibeta, AA407739, other neoplasm, Transcriptome Sequencings, i2pp2afalseChordoma Targeted Sequencing StudyThis Study uses a focused bespoke bait pull down library method to target findings of Chordoma whole genome and whole exome sequencing studies in order to validate findings. This method will also be used on a larger set of tumour only samples in order to find precedence of these findings in a larger set of patient samples.2017-07-26 15:39:24EGAS000010002809606EGAD00001000267EGAC00001000000